Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial Meeting Abstract
| Authors: | Motzer, R. J.; de la Motte Rouge, T.; Harzstark, A. L.; Michaelson, M. D.; Liu, G.; Gruenwald, V.; Ingrosso, A.; Tortorici, M. A.; Bycott, P. W.; Kim, S.; Rini, B. I. |
| Abstract Title: | Axitinib second-line therapy for metastatic renal cell carcinoma (mRCC): Five-year (yr) overall survival (OS) data from a phase II trial |
| Meeting Title: | 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2011 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-05-20 |
| Language: | English |
| ACCESSION: | WOS:000208880300588 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2011.29.15_suppl.4547 |
| Notes: | Meeting Abstract: 4547 -- Source: Wos |
